Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN

Pacira BioSciences, Inc.

2024-Q2 EPS reported $0.58 revenue$345,140,000

Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.
GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.
Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.
CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.
Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.